Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rizatriptan benzoate, quantity: 14.53 mg (equivalent: rizatriptan, qty 10 mg) - tablet, orally disintegrating - excipient ingredients: aspartame; colloidal anhydrous silica; crospovidone; magnesium stearate; mannitol; microcrystalline cellulose; calcium silicate; flavour - rizalt is indicated for the acute treatment of migraine attacks with or without aura.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 314 microgram (equivalent: fentanyl, qty 200 microgram) - tablet, orally disintegrating - excipient ingredients: magnesium stearate; sodium bicarbonate; mannitol; citric acid; sodium starch glycollate type a; sodium carbonate - fentora is indicated for the treatment of breakthrough pain (btp) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 1.257 mg (equivalent: fentanyl, qty 800 microgram) - tablet, orally disintegrating - excipient ingredients: magnesium stearate; citric acid; sodium carbonate; sodium bicarbonate; sodium starch glycollate type a; mannitol - fentora is indicated for the treatment of breakthrough pain (btp) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 157 microgram (equivalent: fentanyl, qty 100 microgram) - tablet, orally disintegrating - excipient ingredients: mannitol; sodium carbonate; sodium bicarbonate; citric acid; sodium starch glycollate type a; magnesium stearate - fentora is indicated for the treatment of breakthrough pain (btp) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 943 microgram (equivalent: fentanyl, qty 600 microgram) - tablet, orally disintegrating - excipient ingredients: sodium bicarbonate; magnesium stearate; sodium carbonate; sodium starch glycollate type a; citric acid; mannitol - fentora is indicated for the treatment of breakthrough pain (btp) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 628 microgram (equivalent: fentanyl, qty 400 microgram) - tablet, orally disintegrating - excipient ingredients: magnesium stearate; sodium carbonate; sodium starch glycollate type a; sodium bicarbonate; citric acid; mannitol - fentora is indicated for the treatment of breakthrough pain (btp) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lansoprazole, quantity: 30 mg - tablet, orally disintegrating - excipient ingredients: hyprolose; iron oxide yellow; magnesium stearate; magnesium carbonate hydrate; polysorbate 80; microcrystalline cellulose; mannitol; iron oxide red; purified water; crospovidone; titanium dioxide; hypromellose; polyacrylate dispersion (30 per cent); purified talc; glyceryl monostearate; triethyl citrate; aspartame; methacrylic acid - ethyl acrylate copolymer (1:1); citric acid; macrogol 6000; flavour; xylitol; calcium hydrogen phosphate - adults:,1.healing and long-term management of reflux oesophagitis.,2.healing and long-term management for patients with duodenal ulcer.,3.healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,4.lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists.,5.eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials).,6.relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia.,paediatric patients 6 to 17 years of age.,1.treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis.,2.healing of erosive oesophagitis.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lansoprazole, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: mannitol; citric acid; hypromellose; aspartame; microcrystalline cellulose; methacrylic acid - ethyl acrylate copolymer (1:1); titanium dioxide; iron oxide yellow; triethyl citrate; purified talc; purified water; magnesium carbonate hydrate; polysorbate 80; hyprolose; polyacrylate dispersion (30 per cent); magnesium stearate; glyceryl monostearate; crospovidone; iron oxide red; macrogol 6000; xylitol; calcium hydrogen phosphate; flavour - adults:,1.healing and long-term management of reflux oesophagitis.,2.healing and long-term management for patients with duodenal ulcer.,3.healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,4.lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists.,5.eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials).,6.relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia.,paediatric patients 6 to 17 years of age.,1.treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis.,2.healing of erosive oesophagitis.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lansoprazole, quantity: 30 mg - tablet, orally disintegrating - excipient ingredients: purified talc; magnesium carbonate hydrate; polyacrylate dispersion (30 per cent); titanium dioxide; triethyl citrate; aspartame; hyprolose; macrogol 6000; magnesium stearate; methacrylic acid - ethyl acrylate copolymer (1:1); hypromellose; crospovidone; citric acid; iron oxide red; glyceryl monostearate; iron oxide yellow; purified water; mannitol; polysorbate 80; microcrystalline cellulose; flavour; xylitol; calcium hydrogen phosphate - adults:,1.healing and long-term management of reflux oesophagitis.,2.healing and long-term management for patients with duodenal ulcer.,3.healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,4.lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists.,5.eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials).,6.relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia.,paediatric patients 6 to 17 years of age.,1.treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis.,2.healing of erosive oesophagitis.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lansoprazole, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: macrogol 6000; magnesium carbonate hydrate; purified water; hypromellose; polyacrylate dispersion (30 per cent); microcrystalline cellulose; triethyl citrate; iron oxide red; polysorbate 80; glyceryl monostearate; citric acid; titanium dioxide; purified talc; hyprolose; iron oxide yellow; methacrylic acid - ethyl acrylate copolymer (1:1); crospovidone; magnesium stearate; mannitol; aspartame; xylitol; calcium hydrogen phosphate; flavour - adults:,1.healing and long-term management of reflux oesophagitis.,2.healing and long-term management for patients with duodenal ulcer.,3.healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,4.lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists.,5.eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials).,6.relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia.,paediatric patients 6 to 17 years of age.,1.treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis.,2.healing of erosive oesophagitis.